Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Documenti analoghi

• Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
  di: Chyla, Brenda, et al.
  Pubblicazione: (2018)
• Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
  di: Owen, C., et al.
  Pubblicazione: (2019)
• Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series
  di: Fabbri, Alberto, et al.
  Pubblicazione: (2020)
• Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
  di: Aldoss, Ibrahim, et al.
  Pubblicazione: (2018)
• The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
  di: Eyre, Toby A., et al.
  Pubblicazione: (2019)